{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:50:06Z","timestamp":1791240606161,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>LAM is a rare multi-cystic lung disease for which treatment with sirolimus is indicated in cases of moderate or severe lung disease or declining lung function. The aim of this study was to describe patients treated with sirolimus for LAM and their outcomes. This retrospective observational study was based on data from the French national health insurance data system (SNDS). All adult women receiving sirolimus were identified in France between 2014 and 2021. In the absence of a specific LAM code in the system, an algorithm was developed to identify patients treated for possible LAM exclusion of other sirolimus indications (transplantation, graft-versus-host disease), or probable LAM (among possible LAM, patients hospitalized for pneumothorax, pleural drainage, pleurisy, ascites, chronic respiratory failure, lung transplantation, or angiomyolipoma). Over the entire study period, 638 patients were considered as treated with sirolimus for possible LAM, including 208 patients treated for \u201cprobable\u201d LAM and 33 patients for TSC-LAM. Median [Q1; Q3] age at index date was 45.0\u202fyears [34.0; 58.5] for patients with probable LAM and 40.0\u202fyears [28.0; 56.0] for patients with TSC-LAM. Overall, the number of incident patients varied from 28 to 96 each year for possible LAM, from 11 to 33 each year for probable LAM and from 1 to 4 patients each year for TSC-LAM patients. In 2021, the incidence rate of patients treated with sirolimus for probable LAM in France was estimated at 0.9 per 1,000,000 French adult women and the prevalence rate at 6.3 per 1,000,000 French adult women. The 5-year survival after sirolimus initiation was 84% (95% CI: 76%; 90%) for probable LAM patients, and 77% (95% CI: 48%; 91%) for TSC-LAM patients. This study provides an updated epidemiological estimate of LAM patients treated with sirolimus in France between 2014 and 2021. Even though some of the results should be interpreted cautiously in the light of limitations related to the use of claims database, evolution of the disease and missing safety data, the information retrieved in this study is very valuable, as few studies provide real-world information on LAM populations.<\/jats:p>","DOI":"10.3389\/fmed.2024.1494713","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:55:31Z","timestamp":1736358931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics and outcomes of patients with LAM receiving sirolimus in France based on real-life data"],"prefix":"10.3389","volume":"11","author":[{"given":"Vincent","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Hirschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallorie","family":"Kerjouan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Diesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieux","family":"Chard\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fi\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine","family":"W\u00e9meau-Stervinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdagul","family":"Uzunhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200409-1298OC","article-title":"The NHLBI Lymphangioleiomyomatosis registry","volume":"173","author":"Ryu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S2213-2600(21)00228-9","article-title":"Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management","volume":"9","author":"McCarthy","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4065\/75.6.591","article-title":"High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex","volume":"75","author":"Costello","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/qjmed\/hcr116","article-title":"Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis","volume":"104","author":"Harknett","year":"2011","journal-title":"QJM Mon J Assoc Physicians"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.rmr.2015.10.005","article-title":"Pulmonary lymphangioleiomyomatosis: from pathogenesis to management","volume":"33","author":"Chebib","year":"2016","journal-title":"Rev Mal Respir"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1164\/ajrccm.151.2.7842216","article-title":"Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors","volume":"151","author":"Kitaichi","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2023.02.026","article-title":"Determinants of progression and mortality in Lymphangioleiomyomatosis","volume":"164","author":"Xu","year":"2023","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/resp.12430","article-title":"Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan","volume":"20","author":"Hasegawa","year":"2015","journal-title":"Respirol Carlton Vic"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1159\/000516330","article-title":"Improving survival in Lymphangioleio-myomatosis: a 16-year observational study in a large cohort of patients","volume":"100","author":"Harari","year":"2021","journal-title":"Respir Int Rev Thorac Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1038\/s41598-022-12314-1","article-title":"Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral Centre in Korea","volume":"12","author":"Chang","year":"2022","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12931-022-02079-6","article-title":"Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis","volume":"23","author":"Yoon","year":"2022","journal-title":"Respir Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1183\/09031936.00076209","article-title":"European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis","volume":"35","author":"Johnson","year":"2010","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e20210337","DOI":"10.36416\/1806-3756\/e20210337","article-title":"Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis","volume":"48","author":"Li","year":"2022","journal-title":"J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","article-title":"Official American Thoracic Society\/Japanese respiratory society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management","volume":"194","author":"McCormack","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.resmer.2023.101010","article-title":"French recommendations for the diagnosis and management of lymphangioleiomyomatosis","volume":"83","author":"Cottin","year":"2023","journal-title":"Respir Med Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf ao\u00fbt"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: what interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev Med Interne"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2213-8587(23)00042-6","article-title":"Rare diseases: individually rare, collectively common","volume":"11","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/thorax.55.12.1052","article-title":"Clinical experience of lymphangioleiomyomatosis in the UK","volume":"55","author":"Johnson","year":"2000","journal-title":"Thorax d\u00e9c"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1494713\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:55:34Z","timestamp":1736358934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1494713\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":22,"alternative-id":["10.3389\/fmed.2024.1494713"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1494713","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1494713"}}